Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
231.25
-9.09 (-3.78%)
At close: Jan 16, 2026, 4:00 PM EST
231.52
+0.27 (0.12%)
After-hours: Jan 16, 2026, 7:03 PM EST
Natera Revenue
Natera had revenue of $592.18M in the quarter ending September 30, 2025, with 34.66% growth. This brings the company's revenue in the last twelve months to $2.12B, up 38.17% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$2.12B
Revenue Growth
+38.17%
P/S Ratio
15.33
Revenue / Employee
$477,374
Employees
4,434
Market Cap
31.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | 40.92M | 287.16% |
| Dec 31, 2012 | 14.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NTRA News
- 2 days ago - Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling - Business Wire
- 4 days ago - Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA - Business Wire
- 4 days ago - Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth - Business Wire
- 9 days ago - Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Business Wire
- 11 days ago - Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI - Business Wire
- 11 days ago - Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology - Business Wire
- 25 days ago - Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire